Late presentation of sorafenib-associated rash: a case report

• Main Authors: Ross Paul, Sarkodie Thomas
• Format: Article
• Language: English
• Published: BMC 2010-10-01
• Series: Journal of Medical Case Reports
• Online Access: http://www.jmedicalcasereports.com/content/4/1/338

<p>Abstract</p> <p>Introduction</p> <p>Sorafenib, an oral multitargeted tyrosine kinase inhibitor, is licensed for the treatment of hepatocellular carcinoma. Rash is one of the most common side effects of its use, generally appearing within days to a few weeks of commencing treatment. We report the first case of rash appearing nine months after starting treatment with sorafenib.</p> <p>Case presentation</p> <p>A 75-year-old Caucasian man initially presented with asymptomatic transient jaundice. He was diagnosed with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma after extensive investigation. He tolerated sorafenib 400 mg twice a day before presenting nine months later with a rash, confirmed to be drug-induced.</p> <p>Conclusions</p> <p>Sorafenib is a drug of choice in Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. It can cause protracted rash quite late into treatment. Successful management of the rash could contribute to achieving stable disease in hepatocellular carcinoma over a significant period of time.</p>